Durkin Brian L 4
4 · AbbVie Inc. · Filed Feb 21, 2023
Insider Transaction Report
Form 4
AbbVie Inc.ABBV
Durkin Brian L
VP, Controller
Transactions
- Award
Common Stock, $0.01 par value
2023-02-16+16,042→ 35,136 total - Award
Common Stock, $0.01 par value
2023-02-16+3,743→ 38,879 total - Award
Common Stock, $0.01 par value
2023-02-16+2,306→ 44,331 total - Award
Common Stock, $0.01 par value
2023-02-16+3,146→ 42,025 total - Award
Option (right to buy)
2023-02-16+6,752→ 6,752 totalExercise: $149.62From: 2024-02-16Exp: 2033-02-15→ Common Stock (6,752 underlying)
Footnotes (5)
- [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
- [F2]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
- [F3]Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
- [F4]Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
- [F5]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 2,251 on February 16, 2024, 2,251 on February 16, 2025, and 2,251 on February 16, 2026.